



Cite this: *Org. Biomol. Chem.*, 2015, **13**, 9673

Convenient synthesis and application of versatile nucleic acid lipid membrane anchors in the assembly and fusion of liposomes†

Oliver Ries, Philipp M. G. Löffler and Stefan Vogel*

Hydrophobic moieties like lipid membrane anchors are highly demanded modifications for nucleic acid oligomers. Membrane-anchor modified oligonucleotides are applicable in biomedicine leading to new delivery strategies as well as in biophysical investigations towards the assembly and fusion of liposomes or the construction of DNA origami structures. We present herein the synthesis and applications of versatile lipid membrane anchor building blocks suitable for solid-supported oligonucleotide synthesis. These are readily synthesized in bulk in five to seven steps from commercially available precursors and can be incorporated at any position within an oligonucleotide without significantly altering the duplex stability and structure as was proven by thermal denaturation experiments and circular dichroism. Furthermore, their applicability could be demonstrated by the assembly and fusion of liposomes mediated by lipid-modified oligonucleotides.

Received 12th June 2015,
Accepted 30th July 2015

DOI: 10.1039/c5ob01207d

www.rsc.org/obc

Introduction

Lipid-oligonucleotide conjugates have been used in biomedical applications to develop new gene therapy strategies using lipidated oligonucleotides as synthetic vectors for the transport of oligonucleotides into cells, for enhancing gene delivery and gene silencing, in the development of new drug delivery systems (*e.g.* utilizing aptamers), as well as for the detection of RNA in living cells.^{1–3} Biophysical and nanotechnological studies encompass the controlled aggregation and fusion of liposomes and their tethering to supported bilayers, the detection of single base mismatches of captured probes by end-point affinity measurements or mass spectrometry, and the construction of artificial devices and DNA origami structures.^{1–5}

The assembly of DNA-functionalized liposomes has been reported earlier by us^{6–8} and others.^{9–11} Hybridization assays based on the thermal denaturation of oligonucleotides and the experimental data gained are crucial for the development and improvement of diagnostic assays targeting, *e.g.*, single nucleotide polymorphism, deletions or insertions.^{12–15}

The fusion of lipid bilayers is a ubiquitous mechanism in nature for the uptake and release of biomolecules, *e.g.* in

signal transduction.¹⁶ Furthermore, liposomes can act as nanocontainers for chemical reagents and catalysts, leading to versatile nanoreactors upon fusion.¹⁷ First attempts made by Boxer^{18,19} and Höök^{20–22} have shown earlier the feasibility of liposome fusion mediated by lipid-oligonucleotide conjugates by mimicking the geometry of the natural SNARE complex.²³

Results and discussion

Lipidated nucleic acid oligomers are often functionalized either on the 5'-end or the 3'-end.¹ Here we introduce lipid membrane anchors derived from enantiomerically pure (*R*)-3-amino-1,2-propanediol (**2**) as building blocks in lipid-DNA conjugates. These are easily accessible in a small number of chemical steps from commercially available compounds and can be incorporated both terminally and internally into a nucleic acid oligomer in good coupling yield (70–90% based on the absorption of cleaved DMTr during synthesis).


Membrane anchor synthesis

Building blocks **1a–c** suitable for solid-supported DNA synthesis using standard phosphoramidite chemistry²⁴ have been prepared from aminodiol **2** in five steps and overall yields of 16–33% (Scheme 1). Aminodiol **2** was chemoselectively acylated with palmitic acid, cholesteryl acid (**S1**) and phytanic acid (**S3**), respectively, utilizing acid chloride chemistry leading to amides **3a–c** in good yield. The presence of magnesium oxide was crucial to prevent side reactions of the free hydroxyl

University of Southern Denmark, Department of Physics, Chemistry and Pharmacy, Campusvej 55, 5230 Odense M, Denmark. E-mail: snv@sdu.dk

† Electronic supplementary information (ESI) available: Synthesis of compounds **3–6a–c** and **S1–S3**, ¹H-, ¹³C- and ³¹P-NMR-spectra of compounds **1–6** and **S1–S3**, characterization of oligonucleotides, DLS and zeta-potential experiments. See DOI: 10.1039/c5ob01207d





Scheme 1 (a) For **3a**: $C_{15}H_{31}COCl$, MgO, H_2O , THF, 0 °C, 4 h; for **3b,c**: **S1** (for **3b**) or **S3** (for **3c**), $SOCl_2$, toluene, reflux, 2 h, then MgO, H_2O , THF, 0 °C, 4–5 h; (b) $LiAlH_4$, THF, reflux, 4 h; (c) for **5a**: $C_{15}H_{31}COCl$, MgO, H_2O , THF, 0 °C, 7 h; for **5b,c**: **S1** (for **5b**) or **S3** (for **5c**), $SOCl_2$, toluene, reflux, 2 h, then MgO, H_2O , THF, 0 °C, 5–6 h; (d) DMTrCl, DMAP, TEA, DCE, 80 °C, 5 h; (e) $iPr_2NPCI(OCH_2CH_2CN)$, DIPEA, DCE, 0 °C, 3–6 h; f) oligonucleotide synthesis.

groups.²⁵ For the synthesis of cholesteryl acid^{26–28} (**S1**) and phytanic acid (**S3**) see ESI.† Direct coupling of phytenic acid (**S2**), an intermediate in the synthesis of **S3**, followed by reduction led to an undesired mixture of the 1,2- and 1,4-reduction products due to the present Michael acceptor (data not shown). Reduction of the amides **3a–c** with lithium aluminium hydride yielded the corresponding secondary amines **4a–c** in excellent yield without the need for further purification. A second acylation step, carried out under the same conditions as those mentioned above, gave di-lipidated amido-

diols **5a–c** in moderate to good yield. DMTr-protection of the primary alcohol under standard conditions and good yield (**6a–c**), followed by phosphoramidite formation resulted in lipid anchor building blocks **1a–c** ready for solid-supported automated DNA synthesis.

Influence on thermal DNA stability

Lipid membrane anchor building blocks **X–Z** have been introduced into DNA oligonucleotides at terminal and internal positions. When incorporated terminally, the modification was followed by a single deoxythymidine to suppress foam-formation of the detergent-like amphiphiles. No evidence could be found that single strands or duplexes were less soluble in aqueous solutions compared to their unlipidated congeners in the concentrations used for the experiments. However, it is recommended to store stock solutions of lipid–DNA conjugates in a ddH_2O /acetonitrile mixture (1 : 1 v/v) as reported by others.¹⁸

The results of thermal denaturation experiments (T_m) are shown in Table 1. It was reported that DNA-amphiphiles might show broad transitions and hysteresis in T_m -experiments.^{8,29–31} All systems presented here gave sharp and clear transitions in UV absorption at 260 nm. Hysteresis was only observed when

Table 1 Influence of membrane anchor monomers **X–Z** on thermal duplex stability

	Sequence ^a	T_m ^b [°C]	ΔT_m ^c [°C]
1	5'-TGT GGA AGA AGT TGG TG 3'-ACA CCT TCT TCA ACC AC	57.7	—
2	5'-TX TGT GGA AGA AGT TGG TG 3'-ACA CCT TCT TCA ACC AC	59.7	2.0
3	5'-TX TGT GGA AGA AGT TGG TG 3'-r(ACA CCU UCU UCA ACC AC)	50.7	−7.0
4	5'-TY TGT GGA AGA AGT TGG TG 3'-ACA CCT TCT TCA ACC AC	55.1	−2.6
5	5'-TZ TGT GGA AGA AGT TGG TG 3'-ACA CCT TCT TCA ACC AC	59.7	2.0
6	5'-TX TGT GGA AGA AGT TGG TG 3'-TX ACA CCT TCT TCA ACC AC	77.1	19.4
7	5'-TY TGT GGA AGA AGT TGG TG 3'-TY ACA CCT TCT TCA ACC AC	86.5	28.8
8	5'-TZ TGT GGA AGA AGT TGG TG 3'-TZ ACA CCT TCT TCA ACC AC	83.5	25.8
9	5'-TX TGT GGA AGA AGT TGG TG 3'-ACA CCT TCT TCA ACC AC XT	59.6	1.9
10	5'-TX TGT GGA AGA AGT TGG TG XT 3'-ACA CCT TCT TCA ACC AC	48.9	−8.8
11	5'-TX TGT GGA AGA AGT TGG TG XT 3'-TX ACA CCT TCT TCA ACC AC XT	85.4	27.7
12	5'-TGA AGA AGG TGT TTG GGA AGA AGT 3'-ACT TCT TCC ACA AAC CCT TCT TCA	63.1	—
13	5'-TGA AGA AGG TGT XTG GGA AGA AGT 3'-ACT TCT TCC ACA AAC CCT TCT TCA	61.6	−1.5
14	5'-TGA AGA AGG TGT XTG GGA AGA AGT 3'-ACT TCT TCC ACA ΦAC CCT TCT TCA	61.9	−1.2
15	5'-TGA AGA AGG TGT XTG GGA AGA AGT 3'-ACT TCT TCC ACA XAC CCT TCT TCA	72.5	9.4

^a X, Y, Z: lipid anchor monomers, Φ: abasic site. ^b Conditions: [HEPES] 10 mM, $[Na^+]$ 110 mM, $[Cl^-]$ 108 mM adjusted to pH 7.0, [DNA] 1 μM each, error ±0.5 °C. ^c Change in T_m value calculated relative to the DNA : DNA reference duplex.



oligonucleotides bearing two **X** modifications, on both the ends of the same strand, were present (Table 1, entries 10 and 11) and in the case of a single modification **Y** (entry 4). Incorporation of modifications **X** and **Z** as overhang in a 17mer DNA sequence led to a slight stabilization of the corresponding dsDNA by $\Delta T_m = 2.0$ °C (entries 2 and 5), whereas modification **Y** at the same position resulted in a decrease of the transition temperature by $\Delta T_m = -2.6$ °C and a hysteresis of approx. 3.9 °C (entry 4). The same DNA strand bearing modification **X** significantly destabilized a DNA/RNA duplex ($\Delta T_m = -7.0$ °C, entry 3). When both DNA strands were modified with the same membrane anchor as overhang on the same side in the duplex, a strong stabilization of the resulting dsDNA could be observed. Stabilization increased thereby from modification **X** ($\Delta T_m = +19.4$ °C, entry 6), over **Z** ($\Delta T_m = +25.8$ °C, entry 8) to **Y** ($\Delta T_m = +28.8$ °C, entry 7). This observation can be explained by the increasing non-polar surface of the different modifications (**X** < **Z** < **Y**), exposed to the aqueous medium upon denaturation of the duplex, and is in accordance with the trend of free energy release for transferring a lipophilic membrane anchor from the aqueous phase to the lipid membrane.^{1,32,33} As the membrane anchors in both strands can interact with each other in the duplex, due to the hydrophobic effect, these attractive forces have to be overcome by thermal energy in the denaturation experiment.³⁴ This argument could be supported by thermal denaturation of dsDNA formed by two 5'-**X**-modified strands, leading to a duplex with membrane anchor modifications on different ends. In this case no interaction of the hydrocarbon chains could be observed ($\Delta T_m = 1.9$ °C, entry 9). In fact, the slight stabilization corresponds well to that found for the single-modified duplex (entry 2).

When modification **X** was introduced as overhang on both sides of a 17mer oligonucleotide, the corresponding dsDNA was significantly destabilized ($\Delta T_m = -8.8$ °C, entry 10) as seen earlier in similar systems.³⁴ Furthermore, a strong hysteresis of 6.9 °C could be observed. This might be explained by the interaction of the hydrocarbon chains forming a hairpin-like structure. Duplex formation has to overcome these hydrophobic interactions. This is in contrast to nucleoside overhangs, which are known to stabilize dsDNA.^{35,36} When both single strands of a duplex bear modification **X** on both the ends, the stabilizing effect could be recovered ($\Delta T_m = +27.7$ °C, entry 11) even though the hysteresis increased to 11.0 °C further indicating intramolecular interactions of the hydrocarbon chains.

Incorporation of modification **X** into the middle of a DNA 24mer resulted in a slight decrease in thermal stability opposite deoxyadenosine ($\Delta T_m = -1.5$ °C, entry 13) as well as an abasic site ($\Delta T_m = -1.2$ °C, entry 14). In contrast, two **X**-units across from each other could stabilize dsDNA ($\Delta T_m = +9.4$ °C, entry 15), even though the effect is not as high as that for terminally modified duplexes.

Circular dichroism

Selected duplexes have been studied by circular dichroism (CD). Fig. 1A shows the CD spectra of selected, terminally




Fig. 1 CD spectra of unmodified DNA and examples of terminally (A) and internally (B) modified DNA duplexes; conditions: [DNA] 1 μ M each, [HEPES] 10 mM, [Na⁺] 110 mM, [Cl⁻] 108 mM, adjusted to pH 7.0.

modified duplexes as well as the unmodified dsDNA as the reference. CD spectra of duplexes terminally modified with lipid membrane anchors **Y** (olive, dotted) and **Z** (red, solid) on both DNA strands (Table 1, entries 7 and 8) are in good agreement with the reference spectrum (Table 1, entry 1) with a minimum at 245 nm and a broad maximum around 275 nm indicating a B-type duplex. The spectrum for the **X**-modified system (orange, dashed, Table 1, entry 6) resembles that of the aforementioned with a broad maximum at 275 nm, but shows a significantly reduced minimum at 245 nm, indicating a distortion of the duplex due to the interactions of the lipid moieties. The duplex consisting of one terminally **X**-modified DNA strand and the corresponding unmodified RNA counter strand (blue, Table 1, entry 3) shows an intense maximum at 266 nm and a weak minimum at 238 nm. This observation agrees with a structure closer to the RNA-A-type conformation than to the DNA-B-type, which is expected for a DNA/RNA hybrid duplex.³⁷ Fig. 1B shows the CD-spectra of 24mers bearing modification **X** in the middle of the strand across an abasic site (orange, dashed, Table 1, entry 14) or another **X**-unit (blue, dotted, Table 1, entry 15) as well as the unmodified DNA/DNA refer-



ence (black, solid, Table 1, entry 12). All spectra show an intense maximum around 277 nm and a weak minimum at 245 nm. Incorporation of modification X seems not to affect the B-type structure when incorporated in the middle of the strand even when two membrane anchor units are placed across from each other.

Assembly of liposomes

In order to prove the usability of the lipid membrane anchors described here, assembly of liposomes has been performed applying the X-modified system from Table 1, entry 9. In this case, the membrane anchors are situated on different ends of the duplex leading to a DNA-tether between the liposomes after incorporation into the lipid bilayer and hybridisation. DNA-functionalized liposomes were prepared by the postinsertion technique.^{7,30,38,39} Successful incorporation of DNA-lipid conjugates into liposomes could be confirmed by a change of zeta-potential upon the addition of different amounts of the conjugates (see ESI† for further details). The data showed no indication of a saturation of the lipophilic reservoir of the liposomes towards the self-inserting amphiphilic oligonucleotides within the range of concentrations used in this study. Assembly and disassembly can be monitored by changes in optical density seen as apparent absorption due to increased light scattering by larger assemblies of liposomes. Fig. 2 shows the normalized apparent absorption at 260 nm for three heating-cooling cycles. Characteristic of this type of experiment is a strong and sharp decrease in apparent absorption upon heating (red curve) at the DNA thermal denaturation temperature. For DNA strands, lipid-modified on both the ends and hybridized with an unmodified DNA counter strand, differences in T_m values of 4–5 °C in the presence and absence of liposomes have been observed.⁷ Here, the difference in T_m values was only 0.5 °C, 60.1 °C in the presence and 59.6 °C in

the absence of liposomes, indicating that attachment to liposomes did not alter the hybridisation of the DNA duplex.

Fusion of liposomes

DNA-lipid conjugates with the same setup have been used to mediate fusion of liposomes.^{18,19,21,22} We tested our system bearing two Z-modifications on the same side in the duplex (“DNA zipper”, Table 1, entry 8) for its fusogenicity with liposomes consisting of DOPC/DOPE/Chol (2 : 1 : 1, molar ratio) applying a frequently used FRET assay.⁴⁰ In brief, one population of liposomes is membrane-labelled with NBD- and Rhodamine-functionalized lipids presenting a FRET pair, whereas a second population remains unlabelled. Upon fusion and mixing of lipids from different liposome populations, the FRET pair gets diluted within the lipid bilayer. Recovery of the NBD-fluorescence can be detected leading to a value for total lipid mixing, the sum of the mixing of the inner and outer lipid layers. For detection of the inner leaflet only, *i.e.* the detection of full fusion only, NBD-fluorophores on the outside can be selectively destroyed, yielding asymmetrically labelled liposomes.⁴¹ A 100% value can be obtained by lysis of the liposomes at the end of the experiment. Fig. 3 shows the normalized fluorescence time scan of NBD emission for a total lipid mixing (■) and a fusion experiment (□) performed with a lipid-DNA conjugate, fitted by a double-exponential curve, and a corresponding control experiment without DNA (total lipid mixing: △, fusion: ▽).²² It can be seen that most of the total lipid mixing, mainly mixing of the outer leaflet, proceeds within the first 5 min of the experiment, but still increases thereafter, while the actual fusion process reaches a maximum after approx. 15 min. From the fitting curves a value of 2.3% for total lipid mixing and 0.9% for fusion can be estimated. The corresponding control experiments showed only traces of total lipid mixing and no fusion. Following the fusion process by DLS led to an increase in the hydrodynamic diameter from




Fig. 2 Assembly of liposomes: liposome–DNA conjugates (100 nM): [POPC] 50 μ M, [DNA] 100 nM (strands: Table 1, entry 9), buffer: [HEPES] 10 mM, [Na⁺] 110 mM, [Cl[−]] 108 mM, adjusted to pH 7.0; d_h : hydrodynamic diameter as determined by DLS (liposomes and DNA strands are not drawn to scale).




Fig. 3 Amount of Total Lipid Mixing (TLM) and Fusion (F) mediated by lipid–DNA conjugates (LiDNA, TLM: ■, F: □) and a control without LiDNA (TLM: △, F: ▽) monitored by fluorescence spectroscopy (solid lines: double-exponential fit).²² DNA strands used: Table 1, entry 8.



117 nm to 125 nm within the first minute. Thereafter the value stayed constant over time (for the graph see ESI†). Even though the system needs further improvement, these first results show that our new membrane anchor incorporated into DNA strands (Table 1, entry 8) is able to mediate fusion between liposomes.

Conclusions

A short and facile synthesis of lipid membrane anchors bearing different lipophilic units suitable for solid-supported DNA synthesis has been achieved. The synthesis is not limited to the lipid moieties shown here, but can be easily extended to other lipophilic units and building blocks bearing two different anchor units. The lipid membrane anchors could be introduced at terminal and internal positions within DNA strands. Thermal denaturation experiments showed that a single lipid membrane anchor in a duplex leads to a weak stabilization or destabilisation ($\Delta T_m = \pm 2$ °C), whereas two modifications across from each other in different strands can stabilize a duplex by up to $\Delta T_m = 29$ °C. The duplex structure of modified dsDNA is not significantly disturbed as shown by CD spectroscopy. First applications towards the assembly and fusion of liposomes have demonstrated the versatility of the lipid membrane anchors described. Depending on the site of attachment of the lipid modification, a DNA strand can either be used for the assembly or for the fusion of liposomes.

Experimental procedures

Materials and methods

400 MHz- ^1H , 101 MHz- ^{13}C , and 126 MHz- ^{31}P NMR spectra were recorded on a Bruker Avance III spectrometer. All ^{13}C and ^{31}P spectra are ^1H -decoupled. All spectra were recorded at 25 °C and were referenced internally to solvent reference frequencies wherever possible. Chemical shifts (δ) are quoted in ppm, and coupling constants (J) are reported in Hz. Indexes a and b indicate diastereotope protons. Assignment of signals was carried out using ^1H , ^1H -COSY, HSQC and HMBC spectra obtained on the spectrometer mentioned above. ESI mass spectrometry was performed on a Bruker micrOTOF-Q II system. MALDI mass spectrometry was performed on a Bruker Daltonics microflex LT or a Bruker Daltonics autoflex III smart-beam spectrometer. UV spectroscopy was carried out on a Varian Cary 100 or Cary 300 spectrometer and CD spectroscopy on a Jasco J-815 CD spectrometer. Fluorescence spectroscopy was performed on a Varian Cary Eclipse Fluorescence Spectrophotometer. Hydrodynamic diameters were determined on a Beckman Coulter DelsaMax Pro or a Malvern Nanosight LM14 instrument.

Solvents and reagents. All reagents were purchased from standard suppliers and lipids were purchased from Avanti Polar Lipids. Reactions involving moisture sensitive reagents were carried out under an atmosphere of nitrogen using

anhydrous solvents. Anhydrous solvents were obtained in the following manner and measured on a Mettler-Toledo C20 Coulometric KF Titrator prior to use: tetrahydrofuran (THF) was dried over activated molecular sieves (3 Å); 1,2-dichloroethane (DCE) was purchased dry in a crown cap bottle. Dichloromethane was purchased in technical quality and distilled. All other solvents were purchased in HPLC grade.

Synthesis of oligonucleotides. Oligonucleotides were synthesized with a DNA synthesizer (Expedite 8909, Applied Biosystems or MerMade4, Bioautomation) on a 0.2 μmol scale using standard phosphoramidite chemistry as described previously.²⁴ Activator42, DCI or tetrazole was used as the activator with coupling times of 15–30 minutes for lipid modifications. Deprotection and cleavage from the solid support were done with conc. ammonia at 55 °C overnight. After removal of the solvent, the residue was extracted two times with 75 μL acetonitrile/water (1 : 1) and purified on an HPLC (Dionex Ultimate 3000, Dionex Acclaim 120 C₁₈ 5 μm 120 Å 4.6 \times 150 mm, 0.05 M TEAA-ACN/water (3 : 1) 10 : 90 \rightarrow 100 : 0, 1 mL min⁻¹) or UPLC system (Thermo Scientific Ultimate 3000, Merck Millipore Chromolith Performance RP18-e 4.6 \times 100 mm, 0.05 M TEAA-ACN/water (3 : 1) 10 : 90 \rightarrow 100 : 0, 1 mL min⁻¹). Fractions were concentrated to dryness, dissolved in acetonitrile/water (1 : 1, v/v) and analysed by MALDI-TOF-MS.

Liposomes. POPC liposomes were obtained by short sonication of a POPC suspension in HEPES buffer and subsequent extrusion through 100 nm polycarbonate filters (10 \times , Northern Lipids Thermobarrel Extruder). The mean hydrodynamic diameter was determined to be 114 nm by nanoparticle tracking analysis (NanoSight®) and liposomes were stored at r.t. until use.

Unlabelled DOPC/DOPE/Chol liposomes (2 : 1 : 1, molar ratio) or labelled liposomes (containing 1.5 mol% NBD-DPPE, 1.5 mol% Rhodamine Lissamine-DPPE) were obtained by mixing lipid stock solutions in CHCl_3 and methanol, evaporation of the organic solvent and drying under vacuum. The lipid film was rehydrated in HEPES buffer, vortexed and extruded through a 100 nm polycarbonate filter (11 \times , Avanti Polar Lipids Handextruder). The mean hydrodynamic diameter was determined to be 131 nm by nanoparticle tracking analysis (NanoSight®) and liposomes were used on the same day.

For asymmetrically labelled liposomes, liposomes containing NBD/Rhodamine were treated with an aliquot of sodium dithionite solution ([sodium dithionite] 55 mM, [HEPES] 10 mM) for 4 min and purified by size exclusion chromatography using a prepacked NAP-10 column (elution buffer: [HEPES] 10 mM, [Na^+] 110 mM, [Cl^-] 108 mM, adjusted to pH 7.0). The liposome concentration was determined by measuring the Rhodamine fluorescence against a standard curve obtained from unreduced liposomes. More reliable results were obtained when the samples were treated with Triton X-100 prior to measurements.

T_m measurements. Thermal denaturation experiments were carried out with solutions of DNA oligomers (1 μM each) in HEPES buffer ([HEPES] 10 mM, [Na^+] 110 mM, [Cl^-] 108 mM, adjusted to pH 7.0, 1 mL total volume) on the instruments



mentioned above. Thermal denaturation temperatures (T_m , °C) were determined as single-peak Gauss fits of first derivatives of melting curves, obtained by recording absorbance at 260 nm as a function of temperature at a rate of 0.5 °C min⁻¹. All samples were heated to 80 °C (or 90 °C/100 °C for systems containing two lipid modifications) before thermal denaturation experiments were performed. All melting temperatures are reported with an uncertainty of ±0.5 °C, as determined from multiple experiments.

CD spectroscopy. CD spectroscopy has been performed on the instrument mentioned above using the samples from T_m measurements. All spectra were recorded at 20 °C and were background-corrected with a spectrum obtained from HEPES buffer.

Assembly experiments. POPC liposomes (50 μM) were treated with the different DNA strands (100 nM) in separate vials and mixed in a UV/Vis cuvette (1 mL total volume). All concentrations are given as final concentrations in the experiment. Measurements were carried out analogous to T_m measurements.

Fusion experiment. Either unlabelled (0.22 mM) or labelled DOPC/DOPE/Chol liposomes (0.055 mM) were incubated in a separate vial with one of the DNA strands (0.168 μ M and 0.084 μ M, respectively) for 15 min at room temperature. Prior to the experiment both solutions were mixed in a fluorescence cuvette (240 μ L total volume) and NBD fluorescence was monitored (excitation: 460 nm, emission: 535 nm). At the end of each experiment, liposomes were destroyed by the addition of Triton X-100 (10 μ L, 1 wt% in water). The amount of total lipid mixing/fusion at a given time t was calculated as follows: whereas I_t is the fluorescence intensity at time t , I_0 at the beginning of the experiment and I_{TX100} after the addition of Triton X-100.

$$\text{amount } [\%]_t = \frac{I_t - I_0}{I_{\text{TX100}} - I_0}$$

The experimental data points were fitted with a double-exponential fit to calculate the average amount of total lipid mixing/fusion using the following formula:²²

$$y(t) = A_0 + A_1(1 - e^{-k_1 t}) + A_2(1 - e^{-k_2 t})$$

Synthetic procedures

General procedure for phosphoramidation (1a-c). 2-Cyanoethyl *N,N*-diisopropylchlorophosphoramidite (CDP, 1.2 eq.) was added to a solution of the alcohol (1.0 eq.) and diisopropylethylamine (DIPEA, 1.2 eq.) in dry DCE at 0 °C. Stirring was continued and the reaction was allowed to reach room temperature. The reaction was quenched by the addition of sat. aq. sodium hydrogen sulfate solution and extraction of the aq. layer with DCE, followed by drying of the combined organic layers over sodium or magnesium sulfate (**1a,b**) or by the addition of ethanol (**1c**) and evaporation of the solvent. The crude product was purified by column chromatography (SiO₂).

2-Cyanoethyl (1-(*R*)-(N-hexadecyl-N-palmitoyl-1-(dimethoxytriphenylmethyl)oxy)-3-amino-2-yl)diisopropylphosphoramidite (**1a**). 1.48 g (1.73 mmol) **6a**, 1.20 mL (7.06 mmol) DIPEA in 15 mL DCE and 0.45 mL (2.02 mmol) CDP were used. Reaction time: 3 h. Column chromatography: petroleum ether/ethyl acetate 4:1, 0.1% TEA. Yield: 1.46 g (1.38 mmol, 80%) as a clear oil. R_f 0.62 (petroleum ether/ethyl acetate 2:1); ^1H NMR (400 MHz, CDCl_3): δ 0.88 (t, 12H, $J = 6.6$, $4\times$ palm-16- H_3), 1.04 (d, 3H, $J = 6.7$, $\text{N}^i\text{Pr-CH}_3$), 1.11 (d, 3H, $J = 6.8$, $\text{N}^i\text{Pr-CH}_3$), 1.13–1.37 (m, 106H, $2\times$ palm-3- H_2 , $4\times$ palm-4- H_2 -15- H_2 , $2\times$ $\text{N}^i\text{Pr-CH}_3$), 1.39–1.67 (m, 8H, $2\times$ palm-3- H_2 , $2\times$ palm-2- H_2), 2.14–2.28 (m, 2H, $1\times$ palm-2- H_2), 2.30–2.46 (m, 4H, $2\times$ CH_2CN , $1\times$ palm-2- H_2), 2.55–2.72 (m, 2H, $2\times$ CH_2CN), 2.99–3.34 (m, 8H, $2\times$ 3- H_2 , $2\times$ palm-1- H_2), 3.38–3.97 (m, 24H, $2\times$ 1- H_2 , $4\times$ $\text{N}^i\text{Pr-CH}$, $2\times$ POCH_2 , $4\times$ DMTr-OCH_3), 4.00–4.13 (m, 1H, $1\times$ 2-H), 4.21–4.37 (m, 1H, $1\times$ 2-H), 6.70–6.91 (m, 4H, DMTr-CH), 7.13–7.38 (m, 7H, DMTr-CH), 7.40–7.53 (m, 2H, DMTr-CH); ^{13}C NMR (101 MHz, CDCl_3): δ 14.24 ($4\times$ palm-C16), 20.13–20.65 ($2\times$ CH_2CN), 22.81, 24.50–24.92, 26.90–27.22, 29.40–29.98, 32.04 ($1\times$ palm-C3, $2\times$ palm-C4-C15, $8\times$ $\text{N}^i\text{Pr-CH}_3$), 25.48–25.72, 27.49, 29.04 ($2\times$ palm-C3, $2\times$ palm-C2), 33.20–33.40 ($1\times$ palm-C2), 33.69–33.83 ($1\times$ palm-C2), 43.04–43.48 ($4\times$ $\text{N}^i\text{Pr-CH}$), 48.49 ($1\times$ C1), 49.40 ($2\times$ palm-C1), 49.79–50.09 ($1\times$ C1), 55.27, 55.30, 55.33 ($4\times$ DMTr-OCH_3), 58.15–58.62 ($2\times$ POCH_2), 64.54–65.03 ($2\times$ C3), 70.84–71.12 ($1\times$ C2), 71.75–72.12 ($1\times$ C2), 85.95, 86.36 (DMTr-CAr_3), 113.10, 113.20, 113.24 (DMTr-CH), 117.47–117.99 ($2\times$ CN), 126.69–126.83, 126.97, 127.14, 127.75–127.98, 128.12–128.45, 129.24, 130.03–130.32 (DMTr-CH), 135.83–136.29, 139.62, 144.74–145.05, 158.44–158.75 (DMTr-C), 173.20–173.52 ($2\times$ palm-CO); ^{31}P NMR (162 MHz, CDCl_3): δ 149.27 (d, $J = 125.16$), 149.47 (d, $J = 51.04$); HRMS (ESI): calcd for $\text{C}_{65}\text{H}_{106}\text{N}_3\text{NaO}_6\text{P}$ m/z 1078.7711 $[\text{M} + \text{Na}]^+$, found 1078.7763.

2-Cyanoethyl 1-(1-(2*R*)-(N-(cholest-5-en-3-carbonyl)-N-(chol-est-5-en-3-methyl)-1-(dimethoxytriphenylmethyloxy)-3-amino-2-yl)diisopropylphosphoramidite (**1b**). 1.03 g (0.88 mmol) **6b**, 0.60 mL (3.53 mmol) DIPEA in 10 mL DCE and 0.25 mL (1.12 mmol) CDP were used. Reaction time: 4 h. Column chromatography: petroleum ether/ethyl acetate 4:1, 0.1% TEA. Yield: 781 mg (0.57 mmol, 65%) as a clear foam. R_f 0.52 (petroleum ether/ethyl acetate 3:1); ^1H NMR (400 MHz, CDCl_3): δ 0.68 (s, 3H, chol-18- H_3), 0.68 (s, 3H, chol-18- H_3), 0.86 (d, 12H, J = 6.6, 2 \times chol-26- H_3 , 2 \times chol-27- H_3), 0.92 (d, 6H, J = 6.2, 2 \times chol-21- H_3), 0.94–1.72 (56H, 2 \times chol-19- H_3 , 4 \times $\text{N}^i\text{Pr-CH}_3$, chol- CH_2 , chol-CH), 1.76–2.09 (m, 12H, chol- CH_2), 2.25–2.77 (m, 4H, CH_2CN , chol- CH_2 , chol-CH), 2.90–3.30 (m, 4H, 3- H_2 , chol- CH_2), 3.32–3.86 (m, 6H, 1- H_2 , POCH_2 , 2 \times $\text{N}^i\text{Pr-CH}$), 3.74–3.85 (m, 6H, 2 \times DMTr-O CH_3), 3.88–4.06 (m, 0.5H, 2-H), 4.19–4.36 (m, 0.5H, 2-H), 5.19–5.36 (m, 2H, 2 \times chol-6-H), 6.78–6.88 (m, 4H, DMTr-CH), 7.15–7.38 (m, 7H, DMTr-CH), 7.39–7.51 (DMTr-CH); ^{13}C NMR (101 MHz, CDCl_3): δ 11.98, 12.01 (chol-C18), 18.87 (chol-C21), 19.58, 19.61, 19.63 (chol-C19), 20.20–20.62 (CH_2CN), 20.99, 21.06, 21.17 (chol- CH_2), 22.96 (chol-C26, chol-C27), 23.97, 24.43 (chol- CH_2), 24.65–24.88 ($\text{N}^i\text{Pr-CH}_3$), 25.68, 26.81 (chol- CH_2), 28.15 (chol-CH), 28.38, 29.84 (chol- CH_2), 31.92, 31.95, 31.99 (chol-CH), 32.02, 32.06 (chol- CH_2), 35.93

(chol-CH), 36.11, 36.34, 37.14, 37.21, 37.23, 37.26, 37.37, 37.40, 37.43 (chol-CH₂), 38.06 (chol-CH), 38.90, 39.18, 39.33, 39.66, 39.94, 39.98 (chol-CH₂), 42.03, 42.17 (chol-CH), 42.44 (chol-C), 43.20–43.47 (N¹Pr-CH), 48.95–49.78 (C1), 50.43, 50.49, 50.53, 50.63 (chol-CH), 54.64 (chol-CH₂), 55.27, 55.29, 55.33 (DMTr-OCH₃), 56.29, 56.33 (chol-CH), 56.94, 56.99 (chol-CH), 58.08–58.57 (POCH₂), 60.51 (chol-C), 85.86, 86.48 (DMTr-CAr₃), 113.12, 113.28 (DMTr-CH), 117.51–117.98 (CN), 119.99, 120.52, 120.65 (chol-C6), 127.99, 130.13, 130.14 (DMTr-CH), 135.97, 136.05, 142.00, 142.03, 142.10, 142.20, 142.53, 144.82, 145.02 (DMTr-C, chol-C), 158.50, 158.54, 158.66 (DMTr-C), 176.02, 176.05, 176.14 (chol-CO); ³¹P NMR (162 MHz, CDCl₃): δ 149.30 (d, *J* = 118.2), 149.50 (d, *J* = 35.2); HRMS (ESI): calcd for C₈₉H₁₃₄N₃NaO₆P *m/z* 1394.9902 [*M* + Na]⁺, found 1394.9962.

2-Cyanoethyl (1-(2*R*)-(N-phytanyl-N-phytanoyl)-1-(dimethoxytriphenylmethyloxy)-3-amino-2-yl)diisopropylphosphoramidite (1c). 500 mg (0.52 mmol) **6c**, 0.35 mL (2.06 mmol) DIPEA in 7 mL DCE and 0.15 mL (0.67 mmol) CDP were used. Reaction time: 6 h. Column chromatography: petroleum ether/ethyl acetate 6 : 1, 0.1% TEA. Yield: 313 mg (0.27 mmol, 52%) as a clear oil. *R*_f 0.48 (petroleum ether/ethyl acetate 3 : 1); ¹H NMR (400 MHz, CDCl₃): δ 0.77–0.94 (m, 30H, phyt-3-CH₃, phyt-7-CH₃, phyt-11-CH₃, phyt-16-H₃), 0.98–1.60 (m, 55H, 1× phyt-2-H₂, 1× phyt-3-H, 2× phyt-4-H₂-6-H₂, 2× phyt-7-H, 2× phyt-8-H₂-10-H₂, 2× phyt-11-H, 2× phyt-12-H₂-14-H₂, N¹Pr-CH₃), 1.64–2.75 (m, 5H, 1× phyt-2-H₂, 1× phyt-3-H, CH₂CN), 1.52 (qqt, 2H, *J* = 6.6, 6.6, 6.6, 2× phyt-15-H), 3.02–3.98 (m, 16H, 1-H₂, 3-H₂, phyt-1-H₂, POCH₂, N¹Pr-CH, DMTr-OCH₃), 4.00–4.14 (m, 0.5H, 2-H), 4.23–4.37 (m, 0.5H, 2-H), 6.73–6.91 (m, 4H, DMTr-CH), 7.13–7.38 (m, 7H, DMTr-CH), 7.40–7.52 (m, 2H, DMTr-CH); ¹³C NMR (101 MHz, CDCl₃): δ 19.27–20.67 (phyt-3-CH₃, phyt-7-CH₃, phyt-11-CH₃, CH₂CN), 22.63, 22.73 (phyt-C16), 22.31–24.96, 30.18–31.16, 32.62–32.99, 37.12–37.76, 39.38 (phyt-C2, phyt-C3-C14, N¹Pr-CH₃), 27.98 (phyt-C15), 40.23–41.18 (phyt-C2), 42.91–43.42 (N¹Pr-CH), 47.58–50.34 (C3, phyt-C1), 55.19 (DMTr-OCH₃), 57.60–58.58 (POCH₂), 64.14–64.86 (C1), 70.74–72.33 (C2), 85.70–86.39 (DMTr-CAr₃), 113.00, 113.15, 126.65, 126.87, 127.70, 127.84, 128.07, 128.14, 128.27, 128.32, 129.89–130.29 (DMTr-CH), 117.29–117.96 (CN), 135.65–136.25, 144.58–145.00, 158.41, 158.57 (DMTr-C), 172.39–172.83 (phyt-CO); ³¹P NMR (162 MHz, CDCl₃): δ 148.82–148.99 (m), 149.30–149.75 (m); HRMS (ESI): calcd for C₇₃H₁₂₂N₃NaO₆P *m/z* 1190.8963 [*M* + Na]⁺, found 1190.8945.

Acknowledgements

This work has been supported by BioNEC, a Centre of Excellence funded by the Villum Foundation for studies on biomolecular nanoscale engineering.

Notes and references

- 1 M. Schade, D. Berti, D. Huster, A. Herrmann and A. Arbuzova, *Adv. Colloid Interface Sci.*, 2014, **208**, 235.

- 2 A. Gissot, M. Camplo, M. W. Grinstaff and P. Barthélémy, *Org. Biomol. Chem.*, 2008, **6**, 1324.
- 3 A. Patwa, A. Gissot, I. Bestel and P. Barthélémy, *Chem. Soc. Rev.*, 2011, **40**, 5844.
- 4 M. Langecker, V. Arnaut, T. G. Martin, J. List, S. Renner, M. Mayer, H. Dietz and F. C. Simmel, *Science*, 2012, **338**, 932.
- 5 K. Göpfrich, T. Zettl, A. E. C. Meijering, S. Hernández-Ainsa, S. Kocabey, T. Liedl and U. F. Keyser, *Nano Lett.*, 2015, **15**, 3134.
- 6 U. Jakobsen and S. Vogel, in *Methods in Enzymology*, ed. N. Düzgüneş, Academic Press, Burlington, 2009, vol. 464, pp. 233–248.
- 7 U. Jakobsen, A. C. Simonsen and S. Vogel, *J. Am. Chem. Soc.*, 2008, **130**, 10462.
- 8 U. Jakobsen and S. Vogel, *Bioconjugate Chem.*, 2013, **24**, 1485.
- 9 C. A. Merkin, R. I. Letsinger, R. C. Mucic and J. J. Storhoff, *Nature*, 1996, **382**, 607.
- 10 S. R. Tabaei, P. Jönsson, M. Brändén and F. Höök, *J. Struct. Biol.*, 2009, **168**, 200.
- 11 T. Maruyama, H. Yamamura, M. Hiraki, Y. Kemori, H. Takata and M. Goto, *Colloids Surf., B*, 2008, **66**, 119.
- 12 R. H. A. M. Vossen, E. Aten, A. Roos and J. T. den Dunnen, *Hum. Mutat.*, 2009, **30**, 860.
- 13 J. S. R. Farrar, H. Gudrun and C. T. Wittwer, in *Molecular Diagnostics*, ed. G. P. Patrinos and W. J. Ansorge, Academic Press, Burlington, 2009, pp. 229–245.
- 14 N. L. Rosi and C. A. Mirkin, *Chem. Rev.*, 2005, **105**, 1547.
- 15 J. C. Keer, in *Essentials of Nucleic Acid Analysis: A Robust Approach*, ed. J. T. Keer and L. Birch, RSC Publishing, Cambridge, 2008, ch. 7, pp. 132–166.
- 16 R. Jahn, T. Lang and T. C. Südhof, *Cell*, 2003, **112**, 519.
- 17 P. A. Beales and T. K. Vanderlick, *Adv. Colloid Interface Sci.*, 2014, **207**, 290.
- 18 Y. M. Chan, B. van Lengerich and S. Boxer, *Biointerphases*, 2008, **3**, FA17.
- 19 Y. M. Chan, B. van Lengerich and S. Boxer, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**, 979.
- 20 F. Höök, G. Stengel, A. B. Dahlin, A. Gunnarsson, M. P. Jonsson, P. Jönsson, E. Reimhult, L. Simonsson and S. Svedhem, *Biointerphases*, 2008, **3**, FA108.
- 21 G. Stengel, R. Zahn and F. Höök, *J. Am. Chem. Soc.*, 2007, **129**, 9584.
- 22 G. Stengel, L. Simonsson, R. A. Campbell and F. Höök, *J. Phys. Chem. B*, 2008, **112**, 8264.
- 23 H. R. Marsden, I. Tomatsu and A. Kros, *Chem. Soc. Rev.*, 2011, **40**, 1572.
- 24 M. H. Caruthers, *Acc. Chem. Res.*, 1991, **24**, 278.
- 25 D. Kim, H. Rho, J. W. You and J. C. Lee, *Tetrahedron Lett.*, 2002, **43**, 277.
- 26 E. J. Corey and R. A. Sneed, *J. Am. Chem. Soc.*, 1953, **75**, 6234.
- 27 W. J. Gensler and G. M. Sherman, *J. Org. Chem.*, 1958, **23**, 1227.



- 28 S. M. Harwood, K. J. Toyne, J. W. Goodby, M. Parsley and G. W. Gray, *Liq. Cryst.*, 2000, **27**, 443.
- 29 R. G. Shea, J. C. Marsters and N. Bischofberger, *Nucleic Acids Res.*, 1990, **18**, 3777.
- 30 B. Waybrant, T. R. Pearce and E. Kokkoli, *Langmuir*, 2014, **30**, 7465.
- 31 C. Gosse, A. Boutorine, I. Aujard, M. Chami, A. Kononov, E. Cogné-Laage, J. Allemand, J. Li and L. Jullien, *J. Phys. Chem. B*, 2004, **108**, 6485.
- 32 C. T. Pool and T. E. Thompson, *Biochemistry*, 1998, **37**, 10246.
- 33 J. R. Silviu, in *Peptide-lipid interactions*, ed. S. A. Simon and T. J. McIntosh, Elsevier, San Diego, 1st edn, 2002, pp. 371–395.
- 34 K. Rohr and S. Vogel, *ChemBioChem*, 2006, **7**, 463.
- 35 H. Rosemeyer and F. Seela, *J. Chem. Soc., Perkin Trans. 2*, 2002, 746.
- 36 F. Seela and R. Kröschel, *Nucleic Acids Res.*, 2003, **31**, 7150.
- 37 N. Sugimoto, M. Katoh, S. Nakano, T. Ohmichi and M. Sasaki, *FEBS Lett.*, 1994, **354**, 74.
- 38 T. Ishida, D. L. Iden and T. M. Allen, *FEBS Lett.*, 1999, **460**, 129.
- 39 J. N. Moreira, T. Ishida, R. Gaspar and T. M. Allen, *Pharm. Res.*, 2002, **19**, 265.
- 40 D. K. Struck, D. Hoekstra and R. E. Pagano, *Biochemistry*, 1981, **14**, 4093.
- 41 J. C. McIntyre and R. G. Sleight, *Biochemistry*, 1991, **30**, 11819.

